Table S2.
Univariate and multivariate analyses of factors influencing the OS of patients with CCA
| Factors | Survival time (months) | P | |||
|---|---|---|---|---|---|
|
| |||||
| Median | 95% CI of median | 3-Year (%) | 5-Year (%) | ||
|
| |||||
| Gender | 0.589 | ||||
| Male (n=38) | 18.51 | 11.88–25.14 | 23.9 | 20.9 | |
| Female (n=58) | 14.14 | 10.39–17.89 | 24.7 | 13.7 | |
| Age | 0.670 | ||||
| ≤60 (n=46) | 14.70 | 7.46–21.93 | 25.2 | 20.4 | |
| >60 (n=50) | 14.53 | 7.87–21.20 | 23.7 | 12.3 | |
| Symptoms | 0.002 | ||||
| Negative (n=16) | 46.26 | 13.92–78.60 | 58.9 | 43.0 | |
| Positive (n=80) | 12.99 | 9.82–16.15 | 17.8 | 11.6 | |
| AST (IU/L) | 0.243 | ||||
| ≤34 (n=51) | 14.40 | 6.89–21.91 | 29.5 | 22.2 | |
| >34 (n=43) | 15.85 | 5.83–25.86 | 20.3 | 11.6 | |
| ALT (IU/L) | 0.426 | ||||
| ≤36 (n=54) | 14.53 | 7.79–21.27 | 27.1 | 19.4 | |
| >36 (n=35) | 15.85 | 8.72–22.97 | 19.6 | 9.8 | |
| ALP (IU/L) | 0.001* | ||||
| ≤94 (n=36) | 26.86 | 14.77–38.95 | 40.3 | 27.5 | |
| >94 (n=55) | 10.72 | 6.29–15.15 | 14.5 | 9.1 | |
| Bilirubin (total) (mg/dL) | 0.392 | ||||
| ≤1.3 (n=82) | 15.81 | 10.07–21.56 | 26.2 | 16.8 | |
| >1.3 (n=14) | 10.72 | 0.00–22.23 | 14.3 | 14.3 | |
| Albumin (g/dL) | 0.023 | ||||
| ≤3.5 (n=23) | 5.75 | 4.06–7.45 | 17.4 | 13 | |
| >3.5 (n=65) | 19.89 | 14.35–25.43 | 25.1 | 15 | |
| Serum CEA (ng/dL) | 0.030 | ||||
| ≤5 (n=37) | 19.17 | 10.82–27.51 | 37.3 | 22.6 | |
| >5 (n=35) | 12.72 | 8.24–17.20 | 8.9 | 8.9 | |
| Margin | <0.001* | ||||
| Negative (n=71) | 19.89 | 14.80–24.98 | 33.6 | 22.8 | |
| Positive (n=25) | 4.70 | 2.69–6.71 | 0 | 0 | |
| Size | 0.006 | ||||
| ≤5 cm (n=41) | 20.88 | 12.58–29.17 | 38.8 | 29.1 | |
| >5 cm (n=52) | 12.89 | 8.76–17.01 | 14.8 | 7.4 | |
| Lymph node | 0.016 | ||||
| Negative (n=63) | 20.88 | 14.11–27.64 | 31.1 | 18.4 | |
| Positive (n=31) | 12.72 | 4.83–20.61 | 12.9 | 12.9 | |
| Histological differentiation | 0.960 | ||||
| Well (n=3) | 6.08 | 0.72–11.45 | 33.3 | 33.3 | |
| Moderate (n=48) | 15.81 | 8.89–22.73 | 26.6 | 18.6 | |
| Poor (n=43) | 14.40 | 10.92–17.88 | 22.9 | 14.6 | |
| Others (n=2) | 10.72 | NA | 0 | 0 | |
| IFI27 expression | <0.001* | ||||
| Low (n=51) | 23.90 | 17.92–29.89 | 34.7 | 29.4 | |
| High (n=45) | 9.73 | 6.64–12.82 | 12.0 | 2.4 | |
| Post-op chemotherapy | 0.383 | ||||
| Without (n=48) | 14.40 | 0.00–30.88 | 33.4 | 23.8 | |
| With (n=48) | 14.70 | 10.34–19.05 | 16.7 | 10.4 | |
| Post-op radiotherapy | 0.075 | ||||
| Without (n=84) | 14.53 | 10.66–18.40 | 28.2 | 19.2 | |
| With (n=12) | 7.17 | 0.00–27.65 | 0 | 0 | |
Note:
*
Means statistically significant in Cox’s proportional hazards analysis; relative risks (P-value) for ALP, margin, and IFI27 expression are 2.17 (0.025), 2.11(0.022), and 2.73 (0.002), respectively. Bold indicates significance in univariate analysis.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCA, cholangiocarcinoma; CEA, carcinoembryonic antigen; IFI27, interferon α-inducible protein 27; IU, international unit; op, operation; OS, overall survival.